SNHG12 and metastatic malignant neoplasm in the lymph nodes: As presented in Table 3 and Figure 6, metaresults showed that elevated SNHG12 expression was found to be closely related to advanced clinical stage (OR = 0.35; 95% CI: 0.21-0.59; P < 0.001), larger tumor size (OR = 0.33; 95% CI: 0.18-0.59; P < 0.001), poor tumor differentiation (OR = 0.41; 95% CI: 0.25-0.69; P = 0.001), lymph node metastasis (LNM) (OR = 0.26; 95% CI: 0.19-0.37; P < 0.001), and distant metastasis (OR = 0.43; 95% CI: 0.22-0.84; P = 0.014).